.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Express Scripts
QuintilesIMS
Baxter
UBS
Federal Trade Commission
Novartis
Fuji
Citi

Generated: September 26, 2017

DrugPatentWatch Database Preview

Irbesartan - Generic Drug Details

« Back to Dashboard

What are the generic sources for irbesartan and what is the scope of irbesartan freedom to operate?

Irbesartan
is the generic ingredient in two branded drugs marketed by West-ward Pharms Int, Cipla Ltd, Hetero Labs Ltd V, Zydus Pharms Usa Inc, Unichem Labs Ltd, Watson Labs Inc, Lupin Ltd, Apotex Inc, Jubilant Generics, Alembic Pharms Ltd, Macleods Pharms Ltd, Sanofi Aventis Us, Teva Pharms, Dr Reddys Labs Ltd, Mylan Pharms Inc, Sandoz, Prinston Inc, Sciegen Pharms Inc, Aurobindo Pharma Ltd, Ajanta Pharma Ltd, and Hisun Pharm Hangzhou, and is included in twenty-one NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-eight drug master file entries for irbesartan. Twenty-three suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: irbesartan

Tradenames:2
Patents:0
Applicants:21
NDAs:21
Drug Master File Entries: see list38
Suppliers / Packagers: see list23
Bulk Api Vendors: see list90
Clinical Trials: see list92
Patent Applications: see list5,439
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:irbesartan at DailyMed

Pharmacology for Ingredient: irbesartan

Tentative approvals for IRBESARTAN

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe150MG; 12.5MGTABLET; ORAL
► Subscribe► Subscribe300MG; 25MGTABLET; ORAL
► Subscribe► Subscribe300MG; 12.5MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cipla Ltd
IRBESARTAN
irbesartan
TABLET;ORAL077205-003Nov 14, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
IRBESARTAN
irbesartan
TABLET;ORAL203161-002Sep 27, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
IRBESARTAN
irbesartan
TABLET;ORAL200461-003Sep 27, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Sciegen Pharms Inc
IRBESARTAN
irbesartan
TABLET;ORAL204774-001Dec 7, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz
IRBESARTAN
irbesartan
TABLET;ORAL077466-003Sep 27, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Watson Labs Inc
IRBESARTAN
irbesartan
TABLET;ORAL090720-002Oct 12, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
IRBESARTAN
irbesartan
TABLET;ORAL203161-003Sep 27, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa Inc
IRBESARTAN
irbesartan
TABLET;ORAL079213-003Sep 27, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Alembic Pharms Ltd
IRBESARTAN
irbesartan
TABLET;ORAL091236-002Oct 15, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
IRBESARTAN
irbesartan
TABLET;ORAL077159-002Mar 30, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: irbesartan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
AVAPRO
irbesartan
TABLET;ORAL020757-001Sep 30, 1997► Subscribe► Subscribe
Sanofi Aventis Us
AVAPRO
irbesartan
TABLET;ORAL020757-002Sep 30, 1997► Subscribe► Subscribe
Sanofi Aventis Us
AVAPRO
irbesartan
TABLET;ORAL020757-002Sep 30, 1997► Subscribe► Subscribe
Sanofi Aventis Us
AVAPRO
irbesartan
TABLET;ORAL020757-003Sep 30, 1997► Subscribe► Subscribe
Sanofi Aventis Us
AVAPRO
irbesartan
TABLET;ORAL020757-001Sep 30, 1997► Subscribe► Subscribe
Sanofi Aventis Us
AVAPRO
irbesartan
TABLET;ORAL020757-003Sep 30, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Chinese Patent Office
Healthtrust
Accenture
US Army
Mallinckrodt
Johnson and Johnson
Medtronic
QuintilesIMS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot